Loading
Adaptin Bio
Adaptin Bio is a North Carolina company working on ways to get immune treatments past the barrier that protects the brain. Its first medicine, APTN-101, is in an early trial at Duke University in glioblastoma.
Also called: Adaptin Bio, Inc.
Overview
Adaptin Bio, Inc., of Charlotte, North Carolina, develops technology originally from the Department of Neurosurgery at Duke University, led by John H. Sampson, that uses activated T cells to carry bound molecules across the blood-brain barrier. Its first platform, BRiTE (Brain Bispecific T-cell Engager), pairs this with a tumour-specific, fully human bispecific antibody. The first product, APTN-101, is an EGFRvIII x CD3 BRiTE. The FDA accepted an investigator-initiated IND in May 2023 and a multi-dose amendment in October 2025, and in August 2026 Duke opened an investigator-initiated phase 1 trial of hEGFRvIII-CD3 bi-scFv in WHO grade 4 malignant glioma.
Headquarters
Charlotte, NC, US
Scorecard
All companies#602of 1706 companies, score 5
- phase 1/2 +1
- targets +2
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
Biotech · APTN
Stage
Public
Website
Products
1Phase 1Bispecific T cell engager (EGFRvIII x CD3)
APTN-101 is a two-armed antibody from Adaptin Bio that steers a patient's own T cells against brain tumour cells carrying a faulty growth receptor. It is in a first trial in people with glioblastoma at Duke University.
Notes
- Read on 4 November 2026 in the S-1 filed with the SEC on 28 August 2026. The trial registry number is not given in the filing.
Connected
5Similar pages
- CompanyJanux Therapeutics
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- CompanyIGM Biosciences
- CompanyXencor
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- TreatmentTB-Bs1
Shares CD3, T-cell engagers (bispecific).
- CompanyHemogenyx Pharmaceuticals
Shares CD3, Bispecific antibodies.
- PersonAjai Chari
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- TreatmentGlyTR1
Shares CD3, T-cell engagers (bispecific).
- CompanyCDR-Life
fronts
technologies
targets
drugs
Phase 1Bispecific T cell engager (EGFRvIII x CD3)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
adaptinbio.com · 1
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/